GSA Capital Partners LLP acquired a new stake in CVS Health Corp (NYSE:CVS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 27,752 shares of the pharmacy operator’s stock, valued at approximately $2,185,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of CVS Health in the second quarter valued at $191,000. Amica Pension Fund Board of Trustees grew its stake in shares of CVS Health by 38.5% in the second quarter. Amica Pension Fund Board of Trustees now owns 40,787 shares of the pharmacy operator’s stock valued at $2,625,000 after buying an additional 11,331 shares in the last quarter. Amica Retiree Medical Trust grew its stake in shares of CVS Health by 34.2% in the second quarter. Amica Retiree Medical Trust now owns 6,383 shares of the pharmacy operator’s stock valued at $411,000 after buying an additional 1,625 shares in the last quarter. Canal Capital Management LLC grew its stake in shares of CVS Health by 5.6% in the second quarter. Canal Capital Management LLC now owns 20,252 shares of the pharmacy operator’s stock valued at $1,303,000 after buying an additional 1,076 shares in the last quarter. Finally, Veritas Investment Management UK Ltd grew its stake in shares of CVS Health by 19.1% in the second quarter. Veritas Investment Management UK Ltd now owns 234,023 shares of the pharmacy operator’s stock valued at $15,059,000 after buying an additional 37,605 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors.
CVS has been the subject of a number of research reports. Bank of America lifted their price objective on CVS Health from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, September 17th. ValuEngine cut CVS Health from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 4th. Tigress Financial reaffirmed a “buy” rating on shares of CVS Health in a research note on Friday, October 26th. Royal Bank of Canada lifted their price objective on CVS Health to $101.00 and gave the company an “outperform” rating in a research note on Tuesday, September 18th. Finally, Wolfe Research initiated coverage on CVS Health in a research note on Thursday, October 25th. They issued a “peer perform” rating for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. CVS Health currently has an average rating of “Buy” and a consensus price target of $90.69.
NYSE:CVS opened at $76.57 on Friday. The firm has a market capitalization of $80.39 billion, a P/E ratio of 12.98, a P/E/G ratio of 1.13 and a beta of 0.98. CVS Health Corp has a 12-month low of $60.14 and a 12-month high of $83.88. The company has a quick ratio of 1.94, a current ratio of 2.44 and a debt-to-equity ratio of 1.66.
CVS Health (NYSE:CVS) last released its earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.71 by $0.02. The firm had revenue of $47.27 billion during the quarter, compared to analyst estimates of $47.22 billion. CVS Health had a return on equity of 18.69% and a net margin of 1.65%. CVS Health’s revenue was up 2.4% compared to the same quarter last year. During the same period last year, the business posted $1.50 earnings per share. Equities research analysts predict that CVS Health Corp will post 7.03 earnings per share for the current year.
In related news, EVP Troyen A. Brennan sold 14,229 shares of CVS Health stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $82.00, for a total value of $1,166,778.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David M. Denton sold 25,159 shares of CVS Health stock in a transaction on Thursday, November 29th. The shares were sold at an average price of $80.13, for a total value of $2,015,990.67. Following the completion of the transaction, the chief financial officer now owns 403 shares of the company’s stock, valued at $32,292.39. The disclosure for this sale can be found here. Over the last quarter, insiders sold 74,233 shares of company stock valued at $5,932,565. 0.53% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by Zolmax and is the sole property of of Zolmax. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://zolmax.com/investing/gsa-capital-partners-llp-invests-2-19-million-in-cvs-health-corp-cvs/2747359.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.